Keytruda

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

decline. Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in

Roche’s Tecentriq combo scores FDA approval for melanoma

However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo which have already been on the market ... In fact, Keytruda was first approved for

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

AZ strengthens Daiichi Sankyo partnership with new ADC deal

The NSCLC market is particularly lucrative, and is currently dominated by Merck &Co’s Keytruda (pembrolizumab), a PD-1 inhibitor which has become a standard treatment for newly-diagnosed NSCLC patients

Tecentriq misses the mark in advanced ovarian cancer

Lung cancer is otherwise dominated by rival PD-1 inhibitor Keytruda (pembrolizumab), marketed by Merck &Co/MSD. ... Keytruda is the leader in the non-small cell lung cancer (NSCLC) market, which accounts for the majority of lung cancer cases.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]